Thrivent Financial for Lutherans’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Thrivent Financial for Lutherans’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-525,010	Closed	-$62.3M	–	2586
2022 Q1	$62.3M	Sell	525,010 -156,662	-23%	-$19.5M	0.12%	209
2021 Q4	$93.9M	Buy	+681,672	New	+$86.7M	0.18%	144
2021 Q3	–	Sell	-1,416,890	Closed	-$138M	–	2530
2021 Q2	$138M	Buy	1,416,890 +919,951	+185%	+$74.7M	0.28%	81
2021 Q1	$34M	Buy	496,939 +1,739	+0.4%	+$141K	0.07%	308
2020 Q4	$42.4M	Sell	495,200 -2,488	-0.5%	-$211K	0.1%	266
2020 Q3	$32.4M	Buy	497,688 +332,014	+200%	+$21.8M	0.09%	279
2020 Q2	$12.1M	Buy	165,674 +64,811	+64%	+$3.45M	0.04%	509
2020 Q1	$3.43M	Buy	+100,863	New	+$4.61M	0.01%	752

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thrivent Financial for Lutherans's BHVN Position: Q2 2022 in Review

Thrivent Financial for Lutherans sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 525,010 shares — an estimated $62.3M sold.

Thrivent Financial for Lutherans first reported a position in BHVN in Q1 2020 and held it in 8 quarters. The position peaked at $138M in Q2 2021. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Thrivent Financial for Lutherans reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Thrivent Financial for Lutherans sold 525,010 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $62.3M.
Thrivent Financial for Lutherans first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2020 and held it in 8 quarters.
Thrivent Financial for Lutherans's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $138M in Q2 2021.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2022, filed 16 Aug 2022.